Summit Global Investments Buys 12,095 Shares of United Therapeutics Co. (NASDAQ:UTHR)

Summit Global Investments boosted its stake in United Therapeutics Co. (NASDAQ:UTHR) by 80.5% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 27,112 shares of the biotechnology company’s stock after acquiring an additional 12,095 shares during the period. Summit Global Investments owned 0.06% of United Therapeutics worth $5,962,000 at the end of the most recent reporting period.

Several other large investors have also added to or reduced their stakes in the stock. GAMMA Investing LLC purchased a new position in United Therapeutics during the fourth quarter valued at $43,000. C M Bidwell & Associates Ltd. purchased a new position in United Therapeutics during the third quarter valued at $91,000. Blue Trust Inc. lifted its position in United Therapeutics by 10.0% during the fourth quarter. Blue Trust Inc. now owns 504 shares of the biotechnology company’s stock valued at $114,000 after buying an additional 46 shares during the period. CWM LLC lifted its position in United Therapeutics by 45.7% during the fourth quarter. CWM LLC now owns 670 shares of the biotechnology company’s stock valued at $147,000 after buying an additional 210 shares during the period. Finally, Synovus Financial Corp purchased a new position in United Therapeutics during the third quarter valued at $203,000. Institutional investors own 94.08% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have commented on the company. StockNews.com lowered United Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Thursday, April 11th. Wedbush reaffirmed an “outperform” rating and issued a $308.00 price target on shares of United Therapeutics in a research report on Thursday, February 22nd. SVB Leerink began coverage on United Therapeutics in a research report on Monday, February 5th. They issued an “outperform” rating and a $330.00 price target for the company. HC Wainwright reaffirmed a “buy” rating and issued a $300.00 price target on shares of United Therapeutics in a research report on Thursday. Finally, Oppenheimer lifted their price target on United Therapeutics from $375.00 to $400.00 and gave the stock an “outperform” rating in a research report on Thursday. One investment analyst has rated the stock with a hold rating and ten have given a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $306.00.

United Therapeutics Stock Performance

NASDAQ UTHR traded up $3.14 during trading hours on Thursday, hitting $258.28. The company’s stock had a trading volume of 541,003 shares, compared to its average volume of 453,213. United Therapeutics Co. has a 12 month low of $204.44 and a 12 month high of $261.54. The company’s 50 day simple moving average is $235.34 and its two-hundred day simple moving average is $229.00. The company has a market cap of $11.46 billion, a P/E ratio of 13.06 and a beta of 0.54. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.41 and a quick ratio of 4.28.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings data on Wednesday, May 1st. The biotechnology company reported $6.17 EPS for the quarter, topping the consensus estimate of $5.63 by $0.54. The company had revenue of $677.70 million during the quarter, compared to the consensus estimate of $620.31 million. United Therapeutics had a return on equity of 17.72% and a net margin of 42.31%. United Therapeutics’s revenue for the quarter was up 33.7% on a year-over-year basis. During the same period last year, the company earned $4.86 EPS. As a group, sell-side analysts expect that United Therapeutics Co. will post 23.45 EPS for the current fiscal year.

Insider Buying and Selling at United Therapeutics

In other United Therapeutics news, EVP Paul A. Mahon sold 6,000 shares of the business’s stock in a transaction dated Thursday, February 15th. The stock was sold at an average price of $215.31, for a total transaction of $1,291,860.00. Following the completion of the sale, the executive vice president now directly owns 36,599 shares in the company, valued at approximately $7,880,130.69. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In related news, Director Nilda Mesa sold 325 shares of the business’s stock in a transaction that occurred on Wednesday, March 27th. The stock was sold at an average price of $237.80, for a total transaction of $77,285.00. Following the completion of the transaction, the director now directly owns 5,373 shares in the company, valued at approximately $1,277,699.40. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, EVP Paul A. Mahon sold 6,000 shares of the business’s stock in a transaction that occurred on Thursday, February 15th. The shares were sold at an average price of $215.31, for a total value of $1,291,860.00. Following the transaction, the executive vice president now owns 36,599 shares of the company’s stock, valued at $7,880,130.69. The disclosure for this sale can be found here. Insiders sold a total of 138,190 shares of company stock worth $32,643,561 in the last three months. 12.50% of the stock is currently owned by company insiders.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.